MB14: Neuroplasticity-based treatment for fibromyalgia, chronic fatigue and multiple chemical sensitivity: feasibility and outcomes (Pearls) (Multimorbidity)
×
Date
11/17/2019
Time
11:00 am - 12:00 pm
Room
Pier 3
Presenters
Dale Guenter, MD, MPH, CCFP,FCFP
Abstract
Context:
Persistent distressing symptoms that are difficult to categorize diagnostically are common in primary care, disabling for people who experience them, and frustrating for those providing care.
Objective:
Evaluate the feasibility of research involving participants in the Dynamic Neural Retreating System (DNRSTM), and impact on a variety of symptoms.
Design:
Quasi-experimental feasibility study with 1 year follow-up and analysis of outcomes for signal of change.
Setting:
8 in-person 5 day training programs in community settings in 4 countries over 1 year.
Population Studied:
102 adults with persistent distressing symptoms who attended a DNRSTM training seminar in one of 4 countries.
Intervention:
Participants attended 28 hours of training in the DNRS™ treatment approach over 5 days. This approach combines aspects of CBT, MBSR and other modalities with the objective of decreasing stimulus of neural pathways involved in the threat response, and increasing stimulus of neural pathways involved in a healthy and adaptive cognitive, emotional and sensory experience.
Outcome Measures:
Primary outcome at 3, 6 and 12 months was health status using SF-36.
Secondary outcomes were chemical sensitivity (MCS) using Quick Environmental Exposure and Sensitivity Inventory (QEESI), fibromyalgia (FM) symptoms with Symptom Impact Questionnaire (SIQR), chronic fatigue (CFS) with Fatigue Severity Scale (FSS), anxiety with Generalized Anxiety Disorder 7-Item Scale (GAD-7) and depression with Patient Health Questionnaire (PHQ-9).
Results:
Feasibility was good with 68% of training program participants agreeing to research, 85% completing at least 1 follow-up time point, and 63% completing 12 month time point.
Baseline SF-36 scores were comparable to fibromyalgia populations described in the literature.
All SF-36 domains improved markedly, with greatest improvement of 45 points for Role Physical (95% C.I. 30.7,59.6).
In addition the proportion of participants meeting criteria for MCS, CFS, FM, depression and anxiety decreased by 61% (FM in SIQR) to 88% (anxiety in GAD-7).
All scores at all follow-up time points showed sustained improvement, and were different from baseline measures with p<0.001.
Conclusions: This study provides support for a unifying theory of central sensitization for many overlapping chronic conditions. Neuroplasticity principles provided improvement in symptoms greater than other approaches in the literature, for this specific population.
Upon completion of this session, participants should be able to:
- Describe the unifying theory of central sensitization, and the role of neuroplasticity, in the pathophysiology of persistent distressing symptoms
- Explain how specific measures may be applied through a quasi experimental study in a treatment population
- Identify which symptoms are likely to improve through neuroplasticity-based treatment